Sangamo Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sangamo Therapeutics sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
Sangamo Therapeutics: 25 sponsored US clinical trials, 1 recruiting.
Sangamo Therapeutics sponsors 25 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 18 completed. 0 of these trials are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Polyneuropathy, with 2 trials.
Top-decile sponsor footprint
Sangamo Therapeutics ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
25 total, page 1 of 1
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
NCT06980948
Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
NCT05145062
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
NCT04628871
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
NCT04046224
A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
NCT03653247
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
NCT03432364
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I
NCT02702115
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
NCT03041324
Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B
NCT02695160
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
NCT02225665
Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
NCT01543152
Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T
NCT04201782
Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
NCT01252641
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
NCT01044654
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT01079325
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
NCT00985517
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
NCT00876863
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT00748501
Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509
NCT00665145
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT00476931
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT00406458
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
NCT00400634
Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease
NCT00252850
Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy
NCT00110500
CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
NCT00087789
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 7 |
What is open in the Sangamo Therapeutics pipeline
1 recruiting of 25 indexed (4% open); 18 completed (72%).
Phase mix: 0 late (III/IV) vs 22 early (I/II) (early-phase heavy).
Top condition: Diabetic Polyneuropathy (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sangamo Therapeutics: open-pipeline peers nationwide
Peers matched on 25 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Sangamo Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 trials (± recruiting share)
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Fisher and Paykel Healthcare · 4% recruiting · 25 trials
- Mesoblast · 4% recruiting · 25 trials
- ResMed · 4% recruiting · 25 trials
- MedtronicNeuro · 4% recruiting · 51 trials
Related
What to do with this Sangamo Therapeutics page
25 registered trials is a research-attention snapshot, not an endorsement of Sangamo Therapeutics or any single study.
- 1 of Sangamo Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetic Polyneuropathy is the condition Sangamo Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Polyneuropathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sangamo Therapeutics pipeline card: 25 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.